Command Palette

Search for a command to run...

Failure Claims

Indexed failure dossiers with primary-source backing.

23 claims indexed
TitleTargetTrialPhaseFailure
May 24, 2026AMAG-423 in severe preeclampsia: a digoxin immune Fab Phase 2b/3a stopped by the DSMB for futilityAMAG-423 (digoxin immune Fab)ATP1A1AMAG Pharmaceuticals, Inc.NCT03008616PHASE2_PHASE3EfficacyOther
May 24, 2026ARO-ANG3 (zodasiran) Phase 2 in HoFH: positive LDL signal, then a quiet business-decision shutdownARO-ANG3 (zodasiran)ANGPTL3Arrowhead PharmaceuticalsNCT05217667Phase 2SponsorMetabolic
May 23, 2026Azenosertib in metastatic triple-negative breast cancer: ZAP-IT closes after Zentalis pulls the program over safetyAzenosertib (ZN-c3)WEE1Filipa Lynce, MD (Dana-Farber Cancer Institute) / Zentalis PharmaceuticalsNCT06351332PHASE1_2SafetyOncology
May 23, 2026MT-1186 oral edaravone in ALS: a Phase 3b extension follows its parent into futilityMT-1186 (oral edaravone)SOD1Tanabe Pharma America, Inc.NCT05151471Phase 3EfficacyNeurology
May 22, 2026BG-60366 in EGFR-mutant NSCLC: a chimeric degrader retired after 33 patients in a saturated landscapeBG-60366EGFRBeOne Medicines (formerly BeiGene)NCT06685718Phase 1SponsorOncology
May 22, 2026OPC-167832 in DBOS and PBOS regimens: the 3-month tuberculosis target slips againOPC-167832 (quabodepistat) within DBOS and PBOS regimensDPRE1Gates Medical Research InstituteNCT05971602Phase 2EfficacyInfectious Disease
May 21, 2026Lerociclib in HR+/HER2- advanced breast cancer: a clean strategic shutdown in a saturated classLerociclib (G1T38)CDK6EQRx, Inc.NCT05085002Phase 2SponsorOncology
May 21, 2026DS-2325a in Netherton syndrome: an anti-KLK5 monoclonal antibody shut down on business groundsDS-2325aKLK5Daiichi SankyoNCT05979831PHASE1_PHASE2SponsorOther
May 20, 2026INB03 in COVID-19 ARDS: Why a Selective Soluble TNF Strategy Did Not Separate From PlaceboINB03 (XPro1595, pegipanermin)TNFINmune Bio, Inc.NCT04370236PHASE2_3EfficacyInfectious Disease
May 20, 2026Daxdilimab in discoid lupus: Amgen walks away from the ILT7 chairDaxdilimab (HZN-7734, MEDI-7734, VIB7734)LILRA4Amgen (formerly Horizon Therapeutics, originally Viela Bio)NCT05591222Phase 2SponsorImmunology
May 20, 2026TOL-3021 SUNRISE: a proinsulin DNA vaccine ran out of biological roomTOL-3021 (BHT-3021)INSTolerion, Inc.NCT03895437Phase 2EfficacyMetabolic
May 20, 2026HexaBody-CD38 (GEN3014) in Relapsed/Refractory Multiple Myeloma: A Better Antibody, A Saturated MarketGEN3014 (HexaBody-CD38)CD38GenmabNCT04824794PHASE1_2SponsorOncology
May 19, 2026Icovamenib in Type 1 Diabetes: Biomea closes COVALENT-112 after a Phase 2 that was never powered to landIcovamenib (BMF-219)MEN1Biomea Fusion Inc.NCT06152042Phase 2SponsorMetabolic
May 19, 2026Onfasprodil (MIJ821) in MDD with suicidal ideation: an NR2B-selective NMDA antagonist that worked for TRD but matched placebo at 24 hoursOnfasprodil (MIJ821)GRIN2BNovartis PharmaceuticalsNCT04722666Phase 2EfficacyNeurology
May 19, 2026MAGNET: lithium in UNC13A-stratified ALS fails the confirmatory testLithium carbonateGSK3BStichting TRICALS FoundationNCT06008249Phase 3BiomarkerNeurology
May 19, 2026AdvanTIG-302: ociperlimab and the slow collapse of TIGIT in NSCLCOciperlimab (BGB-A1217)TIGITBeiGeneNCT04746924Phase 3EfficacyOncology
May 18, 2026BG-89894 (SYH2039): BeOne pulls a MAT2A inhibitor before it can reportBG-89894 (SYH2039)MAT2ABeOne Medicines (BeiGene)NCT06568614Phase 1SponsorOncology
May 18, 2026Tenecteplase in central retinal artery occlusion: REVISION halts a Phase 3 thrombolysis trial for futilityTenecteplase (originally alteplase, switched in protocol V04)PLATUniversity Hospital TuebingenNCT04965038Phase 3EfficacyNeurology
May 18, 2026IMSA101 and the quiet retirement of the STING-agonist hypothesis in oncologyIMSA101STING1ImmuneSensor Therapeutics Inc.NCT05846659Phase 2SponsorOncology
May 18, 2026Tusamitamab ravtansine in 2L NSCLC: when the antigen is real but the ADC is not enoughTusamitamab ravtansine (SAR408701)CEACAM5SanofiNCT04154956Phase 3EfficacyOncology
May 17, 2026Brigimadlin and Brightline-2: Boehringer closes a twenty-year MDM2-p53 betBrigimadlin (BI 907828)MDM2Boehringer IngelheimNCT05512377Phase 2SponsorOncology
May 17, 2026Exicorilant in mCRPC: a fourth failure for the GR-bypass hypothesisExicorilant (CORT125281)NR3C1Corcept TherapeuticsNCT03437941Phase 1/2EfficacyOncology
May 17, 2026Alpelisib in triple-negative breast cancer: EPIK-B3 ends without a signalAlpelisib (BYL719)PIK3CANovartis PharmaceuticalsNCT04251533Phase 3EnrollmentOncology